Business Medical Dialogues
    • facebook
    • twitter
    Login Register
    • facebook
    • twitter
    Login Register
    • Medical Dialogues
    • Speciality Dialogues
    • Education Dialogues
    • Medical Jobs
    • Medical Matrimony
    • MD Brand Connect
    Business Medical Dialogues
    • News
        • Financial Results
        • Hospitals & Diagnostics
        • IT / Health Venture
        • Implants / Devices
        • Insurance
        • Key Movement
        • Pharmaceuticals
        • Policy
        • Technology
        • pharma-news
    • blog
    LoginRegister
    Business Medical Dialogues
    LoginRegister
    • Home
    • News
      • Financial Results
      • Hospitals & Diagnostics
      • IT / Health Venture
      • Implants / Devices
      • Insurance
      • Key Movement
      • Pharmaceuticals
      • Policy
      • Technology
      • pharma-news
    • blog
    • Home
    • Editors Pick
    • DOP Order: NPPA...

    DOP Order: NPPA refixes retail price of Trilosar 6.25, 12.5

    Meghna A SinghaniaWritten by Meghna A Singhania Published On 2019-05-06T11:23:58+05:30  |  Updated On 17 Aug 2021 11:07 AM IST

    New Delhi: Through a recent notification, the government regulatory agency, the National Pharmaceutical Pricing Authority (NPPA) has fixed the retail price of 2 drug formulations namely Losartan + Chlorthalidone + Amlodipine Tablet (TRILOSAR 6.25 ) and Losartan + Chlorthalidone + Amlodipine Tablet (TRILOSAR 12.50)


    The move comes in with the directions given by the Department of Pharmaceuticals (DoP) in consideration of the review orders filed by Torrent Pharma and Unichem Labs to refix the price of Trilosar.


    Trilosar prevents the blood vessels in your body from narrowing, thus lowering your blood pressure and improving the blood circulation. This medication has the ability to lower the possible risk of a stroke in people suffering from any heart condition. Apart from that, it can also slow down kidney damage among people with type 2 diabetes.


    Medical Dialogues had earlier reported that the Department of Pharmaceuticals (DoP) had accepted the review petition of Torrent Pharmaceutical and Unichem Laboratories against price fixation of formulations "Trilosar 6.25" and "Trilosar 12.5" containing three salts, i.e. Losartan potassium 50mg+Chlorthalidone 6.25 mg+Amlodipine 5 mg, directing National Pharmaceutical Pricing Authority (NPPA) to revise the ceiling price of the same.


    Also Read: Refix Ceiling Price of Torrent pharma Trilosar 6.25, 12.5 : DoP directs NPPA


    The companies had alleged that for arriving at the retail price of both the above formulations, NPPA had taken a base of Rs 2.33 per tablet for salt "Amlodipine 5 mg" (which is a scheduled formulation), notified vide SO 1686(E) dated 09.05.2016. However, NPPA had not taken Wholesale Price Index announced in April 2017 for the year 2016 and announced in April 2018 for the year 2017 to arrive the price of the subject formulation.


    The applicants had contended that NPPA should have considered Rs 2.45 base price for Amlodipine which was notified vide SO 1461(E) dated 02.04.2018. 2.4 Moreover, for both the drugs, NPPA had taken a reduction of 20% on the price of Rs 2.33, being a lower price in comparison with the price of Losartan+Clorthalidone.


    After detailed deliberation of the matter, DoP directed the NPPA to refix the retail prices of Trilosar 6.25 and Trilosar 12.5.


    Following DoP's order, NPPA has now fixed the retail price for the said drugs. The details of the drug reads;














































    Sl.

    No.
    Name of the FormulationDosage form & StrengthUnitRetail Price

    (Rs.)
    Review Order number and dateExisting SO number & dateManufacturer & Marketing Company

    respectively
    (1)(2)(3)(4)(5)(6)(7)(8)
    1.Losartan +

    Chlorthalidone + Amlodipine Tablet (TRILOSAR 6.25 )
    Each film coated tablet contains:

    Losartan Potassium IP 50mg, Chlorthalidone IP 6.25mg, Amlodipine Besylate IP eq. to Amlodipine 5mg tablets
    1 Tablet6.8531015/43/2018-

    Pricing dated 14.03.2019
    5638(E) dated 02.11.2018

    (at Sl. No. 39)
    M/s GKM New Pharma Ltd. / M/s Unichem Laboratories Limited
    2.Losartan +

    Chlorthalidone + Amlodipine Tablet (TRILOSAR 12.50)
    Each film coated tablet contains:

    Losartan Potassium IP 50mg, Chlorthalidone IP 12.50mg, Amlodipine Besylate IP eq. to Amlodipine 5mg tablets
    1 Tablet7.1031015/43/2018-

    Pricing dated 14.03.2019
    5638(E) dated 02.11.2018

    (at Sl. No. 40)
    M/s GKM New Pharma Ltd. / M/s Unichem Laboratories Limited

    The notice further adds;




    • The manufacturer of above mentioned formulations i.e. "new drug" under paragraph 2(u) of the DPCO, 2013 shall fix the retail price as specified in column (5) of the table

    • The manufacturer may add goods and services tax only if they have paid actually or it is payable to the Government on the retail price mentioned in column (5) of the above said

    • The retail price for a pack of the aforesaid formulation shall be arrived at by the concerned manufacturer in accordance with the retail price specified in column (5) of the above table as per provisions contained in paragraph 11 of the DPCO, 2013. The manufacturer shall issue a price list in Form–V from date of Notification as per paragraph 24 of the DPCO, 2013 to NPPA through IPDMS and submit a copy to State Drug Controller and

    • As per para 24(4) of DPCO 2013, every retailer and dealer shall display price list and the supplementary price list, if any, as furnished by the manufacturer, on a conspicuous part of the premises where he carries on business in a manner so as to be easily accessible to any person wishing to consult the

    • The above mentioned retail prices are applicable only to the manufacturer / marketer as mentioned above for generic/ any brand of the same composition / strength of the subject formulations, subject to fulfillment of all the applicable statutory requirements as laid down by the Govt. under relevant statutes/ rules, including manufacturing license permission from the Competent Authority i.e. the Central/State Licensing Authority, as may be applicable, by the concerned manufacturers/marketing companies.

    • In case the retail price of any of the aforesaid formulations is not complied with, as per instant price notification and notes specified hereinabove, then the concerned manufacturer/marketing company shall be liable to deposit the overcharged amount along with the interest thereon under the provisions of the DPCO, 2013 read with the Essential Commodities Act,

    Amlodipine Tabletceiling priceChlorthalidoneclorthalidoneDepartment of PharmaceuticalsDOPDPCOLosartanLosartan+clorthalidonemedicineMRPNational Pharmaceutical Pricing AuthorityNPPApetitionpharmapharma newspharma news indiaretail priceTorrentTorrent petitionTorrent PharmaTrilosarUnichem Labs

    Disclaimer: This site is primarily intended for healthcare professionals. Any content/information on this website does not replace the advice of medical and/or health professionals and should not be construed as medical/diagnostic advice/endorsement or prescription. Use of this site is subject to our terms of use, privacy policy, advertisement policy. © 2020 Minerva Medical Treatment Pvt Ltd

    Meghna A Singhania
    Meghna A Singhania

      Meghna A Singhania is the founder and Editor-in-Chief at Medical Dialogues. An Economics graduate from Delhi University and a post graduate from London School of Economics and Political Science, her key research interest lies in health economics, and policy making in health and medical sector in the country. She can be contacted at editorial@medicaldialogues.in. Contact no. 011-43720751

      Show Full Article
      Next Story
      Similar Posts
      NO DATA FOUND

      Popular Stories

      • Email: info@medicaldialogues.in
      • Phone: 011 - 4372 0751

      Website Last Updated On : 13 Oct 2022 5:14 AM GMT
      Company
      • About Us
      • Contact Us
      • Our Team
      • Reach our Editor
      • Feedback
      • Submit Article
      Ads & Legal
      • Advertise
      • Advertise Policy
      • Terms and Conditions
      • Privacy Policy
      • Editorial Policy
      • Comments Policy
      • Disclamier
      Medical Dialogues is health news portal designed to update medical and healthcare professionals but does not limit/block other interested parties from accessing our general health content. The health content on Medical Dialogues and its subdomains is created and/or edited by our expert team, that includes doctors, healthcare researchers and scientific writers, who review all medical information to keep them in line with the latest evidence-based medical information and accepted health guidelines by established medical organisations of the world.

      Any content/information on this website does not replace the advice of medical and/or health professionals and should not be construed as medical/diagnostic advice/endorsement or prescription.Use of this site is subject to our terms of use, privacy policy, advertisement policy. You can check out disclaimers here. © 2025 Minerva Medical Treatment Pvt Ltd

      © 2025 - Medical Dialogues. All Rights Reserved.
      Powered By: Hocalwire
      X
      We use cookies for analytics, advertising and to improve our site. You agree to our use of cookies by continuing to use our site. To know more, see our Cookie Policy and Cookie Settings.Ok